Results of a Randomized Open Multicenter Comparative Study of the Tolerability and Safety of Gilenya (fingolimod) in Patients with Remitting Multiple Sclerosis (the GIMN study)
Disease-modifying drugs (DMD) are currently used in the treatment of patients with multiple sclerosis (MS) in accordance with therapeutic standards, with the aim of decreasing the risk of developing exacerbations and thus reducing the rate of development of disability. However, the use of first-line substances is not successful in all cases. Second-line agents are used in this situation, which on the territories of the Russian Federation include fingolimod. Experience in the use of fingolimod in routine neurological practice was obtained by performing the postmarketing GIMN trial.
Keywordsmultiple sclerosis fingolimod quality of life compliance
Unable to display preview. Download preview PDF.
- 2.L. Kappos et al., “Long-term efficacy and safety of fingolimod (FTY720) in relapsing-remitting multiple sclerosis (RRMS): Results from the extension of the phase III FREEDOMS study,” ECTRIMS 2012, Poster P979.Google Scholar
- 5.X. Montalban, “From long-term treatment monitoring, Long-term comparison of fingolimod with interferon-beta-1a: results of 4.5-year follow-up from the extension phase III TRANSFORMS study,” Abstr. ECTRIMS 2012.Google Scholar
- 10.M. J. Atkinson, A. Sinha, S. L. Hass, et al., “Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease,” Health Qual. Life Outcomes, 2, 12 (2004).CrossRefPubMedPubMedCentralGoogle Scholar